JP2015145410A5 - - Google Patents

Download PDF

Info

Publication number
JP2015145410A5
JP2015145410A5 JP2015079415A JP2015079415A JP2015145410A5 JP 2015145410 A5 JP2015145410 A5 JP 2015145410A5 JP 2015079415 A JP2015079415 A JP 2015079415A JP 2015079415 A JP2015079415 A JP 2015079415A JP 2015145410 A5 JP2015145410 A5 JP 2015145410A5
Authority
JP
Japan
Prior art keywords
composition according
tablet
composition
substituted
disintegrant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015079415A
Other languages
English (en)
Japanese (ja)
Other versions
JP6147290B2 (ja
JP2015145410A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015145410A publication Critical patent/JP2015145410A/ja
Publication of JP2015145410A5 publication Critical patent/JP2015145410A5/ja
Application granted granted Critical
Publication of JP6147290B2 publication Critical patent/JP6147290B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2015079415A 2005-11-17 2015-04-08 医薬組成物 Expired - Fee Related JP6147290B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73763105P 2005-11-17 2005-11-17
US60/737,631 2005-11-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012135063A Division JP6049317B2 (ja) 2005-11-17 2012-06-14 医薬組成物

Publications (3)

Publication Number Publication Date
JP2015145410A JP2015145410A (ja) 2015-08-13
JP2015145410A5 true JP2015145410A5 (cg-RX-API-DMAC7.html) 2015-09-24
JP6147290B2 JP6147290B2 (ja) 2017-06-14

Family

ID=37875983

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008541365A Withdrawn JP2009515993A (ja) 2005-11-17 2006-11-16 医薬組成物
JP2012135063A Expired - Fee Related JP6049317B2 (ja) 2005-11-17 2012-06-14 医薬組成物
JP2015079415A Expired - Fee Related JP6147290B2 (ja) 2005-11-17 2015-04-08 医薬組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2008541365A Withdrawn JP2009515993A (ja) 2005-11-17 2006-11-16 医薬組成物
JP2012135063A Expired - Fee Related JP6049317B2 (ja) 2005-11-17 2012-06-14 医薬組成物

Country Status (10)

Country Link
US (3) US20080255048A1 (cg-RX-API-DMAC7.html)
EP (1) EP1951207A2 (cg-RX-API-DMAC7.html)
JP (3) JP2009515993A (cg-RX-API-DMAC7.html)
KR (2) KR20140053419A (cg-RX-API-DMAC7.html)
CN (1) CN101309674A (cg-RX-API-DMAC7.html)
AU (1) AU2006318815B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0618723A2 (cg-RX-API-DMAC7.html)
CA (1) CA2626933C (cg-RX-API-DMAC7.html)
RU (1) RU2469709C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007061829A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
AU2006318815B2 (en) * 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Glp-1 펩티드의 조성물 및 그것의 제조
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
WO2016128972A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
MX2019001850A (es) * 2016-08-17 2019-05-15 Entera Bio Ltd Formulaciones para administracion oral de principios activos.
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536A (en) 1837-12-26 Beady binder for binding newspapers
US5773A (en) 1848-09-19 Sizing and drying cotton-batting
US5866A (en) 1848-10-17 Dentist s deill
US608618A (en) 1898-08-09 Thomas millen
US647A (en) 1838-03-21 Improved fishing-seine for deep water
AU508480B2 (en) * 1977-04-13 1980-03-20 Asahi Kasei Kogyo Kabushiki Kaisha Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JP2609022B2 (ja) * 1990-11-29 1997-05-14 北陸製薬株式会社 ポリカルボフィルカルシウム含有製剤
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
ZA961018B (en) * 1995-02-08 1997-08-08 Yamanouchi Europ Bv Oral dosage-forms containing a beta-lactam antibiotic.
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
EP1313699B1 (en) 2000-08-29 2010-03-10 Biocon Limited 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
JP5073153B2 (ja) * 2001-06-01 2012-11-14 ノバルティス アーゲー 副甲状腺ホルモンおよびカルシトニンの経口投与
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
MXPA05002728A (es) * 2002-09-13 2005-07-25 Cydex Inc Capsulas que contienen composiciones de relleno acuoso estabilizadas con ciclodextrina derivada.
JP2007525472A (ja) * 2003-07-04 2007-09-06 ニコメド ダンマーク エイピーエス 経口使用のための副甲状腺ホルモン(pth)含有医薬組成物
PT2316473E (pt) 2003-07-23 2013-09-20 Novartis Ag Utilização de calcitonina na osteoartrite
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
AU2006318815B2 (en) * 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition

Similar Documents

Publication Publication Date Title
JP2021191784A5 (cg-RX-API-DMAC7.html)
JP2024516371A5 (cg-RX-API-DMAC7.html)
JP2019048894A5 (cg-RX-API-DMAC7.html)
EP4483882A3 (en) New methylquinazolinone derivatives
JP2019511550A5 (cg-RX-API-DMAC7.html)
JP2012509348A5 (cg-RX-API-DMAC7.html)
JP2017506627A5 (cg-RX-API-DMAC7.html)
JP2020097577A5 (cg-RX-API-DMAC7.html)
JP2016534063A5 (cg-RX-API-DMAC7.html)
JP2017523225A5 (cg-RX-API-DMAC7.html)
BRPI0511327B8 (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
RU2013119966A (ru) Композиция, улучшающая растворимость плохорастворимого лекарственного препарата
JP2009537538A5 (cg-RX-API-DMAC7.html)
JP2019516735A5 (cg-RX-API-DMAC7.html)
JP2017511377A5 (cg-RX-API-DMAC7.html)
JP2015510916A5 (cg-RX-API-DMAC7.html)
JP2019519533A5 (cg-RX-API-DMAC7.html)
MX2012008413A (es) Composicion novedosa de retigabina.
JP2010521516A5 (cg-RX-API-DMAC7.html)
JOP20170197B1 (ar) الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول
CY1120852T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας
JP2008519768A5 (cg-RX-API-DMAC7.html)
JP2019151627A5 (cg-RX-API-DMAC7.html)
RU2008108516A (ru) 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ
ZA202205756B (en) Oral formulation of x842